Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc.verified

ADVM

Price:

$6.59

Market Cap:

$136.79M

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorpor...[Read more]

Industry

Biotechnology

IPO Date

2014-07-31

Stock Exchange

NASDAQ

Ticker

ADVM

The PE Ratio as of June 2024 (TTM) for Adverum Biotechnologies, Inc. (ADVM) is -0.65

According to Adverum Biotechnologies, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.65. This represents a change of -53.03% compared to the average of -1.38 of the last 4 quarters.

Adverum Biotechnologies, Inc. (ADVM) Historical PE Ratio (quarterly & annually)

How has ADVM PE Ratio performed in the past?

The mean historical PE Ratio of Adverum Biotechnologies, Inc. over the last ten years is -61.94. The current -0.65 PE Ratio has changed 4.94% with respect to the historical average. Over the past ten years (40 quarters), ADVM's PE Ratio was at its highest in in the December 2022 quarter at -0.44. The PE Ratio was at its lowest in in the December 2014 quarter at -295.62.

Quarterly (TTM)
Annual

Average

-61.94

Median

-10.35

Minimum

-483.67

Maximum

-0.37

Adverum Biotechnologies, Inc. (ADVM) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Adverum Biotechnologies, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 194.52%

Maximum Annual PE Ratio = -0.37

Minimum Annual Increase = -89.43%

Minimum Annual PE Ratio = -483.67

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.6573.95%
2022-0.37-68.58%
2021-1.19-84.91%
2020-7.85-31.41%
2019-11.45-56.98%
2018-26.62-2.19%
2017-27.22194.52%
2016-9.24-81.92%
2015-51.12-89.43%
2014-483.67-56.12%

Adverum Biotechnologies, Inc. (ADVM) Average PE Ratio

How has ADVM PE Ratio performed in the past?

The current PE Ratio of Adverum Biotechnologies, Inc. (ADVM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-0.74

5-year avg

-4.30

10-year avg

-61.94

Adverum Biotechnologies, Inc. (ADVM) PE Ratio vs. Peers

How is ADVM’s PE Ratio compared to its peers?

Adverum Biotechnologies, Inc.’s PE Ratio is greater than uniQure N.V. (-0.74), greater than Rocket Pharmaceuticals, Inc. (-7.76), greater than Rhythm Pharmaceuticals, Inc. (-9.09), greater than Solid Biosciences Inc. (-2.87), greater than MeiraGTx Holdings plc (-3.69), less than Aerovate Therapeutics, Inc. (-0.48), greater than Adagene Inc. (-4.08), greater than Acrivon Therapeutics, Inc. Common Stock (-2.34), greater than Rezolute, Inc. (-3.39), greater than AN2 Therapeutics, Inc. (-0.90), less than Passage Bio, Inc. (-0.64), greater than Absci Corporation (-3.17), less than Kezar Life Sciences, Inc. (-0.47), greater than Oncternal Therapeutics, Inc. (-0.65), less than Kodiak Sciences Inc. (-0.59), less than Galmed Pharmaceuticals Ltd. (-0.29), greater than Affimed N.V. (-0.92), greater than Mereo BioPharma Group plc (-79.27), less than Homology Medicines, Inc. (-0.01), greater than Stoke Therapeutics, Inc. (-6.42), less than Atreca, Inc. (-0.04), less than TCR2 Therapeutics Inc. (-0.44),

Build a custom stock screener for Adverum Biotechnologies, Inc. (ADVM) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Adverum Biotechnologies, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Adverum Biotechnologies, Inc. (ADVM) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Adverum Biotechnologies, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Adverum Biotechnologies, Inc.'s PE Ratio?

How is the PE Ratio calculated for Adverum Biotechnologies, Inc. (ADVM)?

What is the highest PE Ratio for Adverum Biotechnologies, Inc. (ADVM)?

What is the 3-year average PE Ratio for Adverum Biotechnologies, Inc. (ADVM)?

What is the 5-year average PE Ratio for Adverum Biotechnologies, Inc. (ADVM)?

How does the current PE Ratio for Adverum Biotechnologies, Inc. (ADVM) compare to its historical average?